Thyroid-stimulating hormone is associated with differential antidepressant and anti-anhedonic response to ketamine in bipolar depression but not major depressive disorder
Journal of Affective Disorders · 2026
DOI: 10.1016/j.jad.2025.120780 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2026. Verfasst von Brady D Greene und 7 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Anhedonia, Antidepressive Agents, Bipolar Disorder, Major Depressive Disorder. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Institutes of Health, National Institute of Mental Health.
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: No clinically useful biomarkers currently predict antidepressant response to ketamine in treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD). This study investigated whether baseline thyroid-stimulating hormone (TSH) levels are associated with ketamine's antidepressant, anti-anhedonic, and anti-suicidal effects. METHODS: This was a secondary exploratory analysis of data drawn from four NIH-sponsored, randomized, placebo-controlled, double-blind crossover studies of ketamine in inpatients with current MDD (n = 39) or bipolar depression (n = 44). Baseline TSH levels were measured before the first intravenous saline or ketamine infusion (0.5 mg/kg). A two-week washout preceded the second infusion. Depression and anhedonia were measured with the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Snaith-Hamilton Pleasure Scale, respectively. Suicidal ideation (SI) was measured as a weighted average of the Beck Depression Inventory and the MADRS suicide items. Linear mixed models were used to evaluate baseline TSH levels as a moderator of response to ketamine (versus placebo), controlling for thyroid disease, lithium use, and depression severity at 230 min and days 1, 2, and 7 post-infusion. RESULTS: In individuals with BD, higher baseline TSH levels were associated with greater decreases in the severity of depressive (drug*TSH, p < 0.0007) and anhedonia (drug*TSH, p < 0.0001) symptoms post-ketamine. TSH levels were not associated with changes in depression, anhedonia, or SI severity in MDD post-ketamine. CONCLUSION: Baseline TSH levels were associated with ketamine's antidepressant and anti-anhedonic effects in BD but not MDD. These findings suggest that TSH may serve as a predictive biomarker of response and highlight a potential thyroid-glutamate influence in ketamine's mechanism of action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
- Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. Electronic address: adam.fijtman@nih.gov.
Förderung
- Intramural NIH HHS
- National Institutes of Health
- National Institute of Mental Health
Zitieren
APA
Greene, B. D., Fijtman, A., Yalin, N., Kvarta, M. D., Wang, P. R., Yavi, M., Greenstein, D., & Zarate, C. A. (2026). Thyroid-stimulating hormone is associated with differential antidepressant and anti-anhedonic response to ketamine in bipolar depression but not major depressive disorder. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.120780
Vancouver
Greene BD, Fijtman A, Yalin N, Kvarta MD, Wang PR, Yavi M, et al. Thyroid-stimulating hormone is associated with differential antidepressant and anti-anhedonic response to ketamine in bipolar depression but not major depressive disorder. Journal of Affective Disorders. 2026. doi:10.1016/j.jad.2025.120780
BibTeX
@article{Greene2026,
author = {Greene, Brady D and Fijtman, Adam and Yalin, Nefize and Kvarta, Mark D and Wang, Philip R and Yavi, Mani and Greenstein, Dede and Zarate, Carlos A},
title = {Thyroid-stimulating hormone is associated with differential antidepressant and anti-anhedonic response to ketamine in bipolar depression but not major depressive disorder},
journal = {Journal of Affective Disorders},
year = {2026},
doi = {10.1016/j.jad.2025.120780}
}
EUVIMED